Ciarán P Kelly1, Joseph A Murray2, Daniel A Leffler3, Daniel R Getts4, Adam C Bledsoe5, Glennda Smithson6, M Roy First7, Amy Morris7, Michael Boyne7, Adam Elhofy7, Tsung-Teh Wu8, Joseph R Podojil4, Stephen D Miller9. 1. Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. 2. Mayo Clinic, Rochester, Minnesota. 3. Beth Israel Deaconess Medical Center, Harvard Medical School Celiac Research Program, Boston, Massachusetts; Takeda Pharmaceuticals International Co., Cambridge, Massachusetts. 4. COUR Pharmaceuticals Development Co, Inc, Northbrook, Illinois; Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 5. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. 6. Takeda Pharmaceuticals International Co., Cambridge, Massachusetts. 7. COUR Pharmaceuticals Development Co, Inc, Northbrook, Illinois. 8. Department of Pathology, Mayo Clinic, Rochester, Minnesota. 9. Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Electronic address: s-d-miller@northwestern.edu.
Abstract
BACKGROUND & AIMS: In celiac disease (CeD), gluten induces immune activation, leading to enteropathy. TAK-101, gluten protein (gliadin) encapsulated in negatively charged poly(dl-lactide-co-glycolic acid) nanoparticles, is designed to induce gluten-specific tolerance. METHODS: TAK-101 was evaluated in phase 1 dose escalation safety and phase 2a double-blind, randomized, placebo-controlled studies. Primary endpoints included pharmacokinetics, safety, and tolerability of TAK-101 (phase 1) and change from baseline in circulating gliadin-specific interferon-γ-producing cells at day 6 of gluten challenge, in patients with CeD (phase 2a). Secondary endpoints in the phase 2a study included changes from baseline in enteropathy (villus height to crypt depth ratio [Vh:Cd]), and frequency of intestinal intraepithelial lymphocytes and peripheral gut-homing T cells. RESULTS: In phase 2a, 33 randomized patients completed the 14-day gluten challenge. TAK-101 induced an 88% reduction in change from baseline in interferon-γ spot-forming units vs placebo (2.01 vs 17.58, P = .006). Vh:Cd deteriorated in the placebo group (-0.63, P = .002), but not in the TAK-101 group (-0.18, P = .110), although the intergroup change from baseline was not significant (P = .08). Intraepithelial lymphocyte numbers remained equal. TAK-101 reduced changes in circulating α4β7+CD4+ (0.26 vs 1.05, P = .032), αEβ7+CD8+ (0.69 vs 3.64, P = .003), and γδ (0.15 vs 1.59, P = .010) effector memory T cells. TAK-101 (up to 8 mg/kg) induced no clinically meaningful changes in vital signs or routine clinical laboratory evaluations. No serious adverse events occurred. CONCLUSIONS: TAK-101 was well tolerated and prevented gluten-induced immune activation in CeD. The findings from the present clinical trial suggest that antigen-specific tolerance was induced and represent a novel approach translatable to other immune-mediated diseases. ClinicalTrials.gov identifiers: NCT03486990 and NCT03738475.
BACKGROUND & AIMS: In celiac disease (CeD), gluten induces immune activation, leading to enteropathy. TAK-101, gluten protein (gliadin) encapsulated in negatively charged poly(dl-lactide-co-glycolic acid) nanoparticles, is designed to induce gluten-specific tolerance. METHODS: TAK-101 was evaluated in phase 1 dose escalation safety and phase 2a double-blind, randomized, placebo-controlled studies. Primary endpoints included pharmacokinetics, safety, and tolerability of TAK-101 (phase 1) and change from baseline in circulating gliadin-specific interferon-γ-producing cells at day 6 of gluten challenge, in patients with CeD (phase 2a). Secondary endpoints in the phase 2a study included changes from baseline in enteropathy (villus height to crypt depth ratio [Vh:Cd]), and frequency of intestinal intraepithelial lymphocytes and peripheral gut-homing T cells. RESULTS: In phase 2a, 33 randomized patients completed the 14-day gluten challenge. TAK-101 induced an 88% reduction in change from baseline in interferon-γ spot-forming units vs placebo (2.01 vs 17.58, P = .006). Vh:Cd deteriorated in the placebo group (-0.63, P = .002), but not in the TAK-101 group (-0.18, P = .110), although the intergroup change from baseline was not significant (P = .08). Intraepithelial lymphocyte numbers remained equal. TAK-101 reduced changes in circulating α4β7+CD4+ (0.26 vs 1.05, P = .032), αEβ7+CD8+ (0.69 vs 3.64, P = .003), and γδ (0.15 vs 1.59, P = .010) effector memory T cells. TAK-101 (up to 8 mg/kg) induced no clinically meaningful changes in vital signs or routine clinical laboratory evaluations. No serious adverse events occurred. CONCLUSIONS: TAK-101 was well tolerated and prevented gluten-induced immune activation in CeD. The findings from the present clinical trial suggest that antigen-specific tolerance was induced and represent a novel approach translatable to other immune-mediated diseases. ClinicalTrials.gov identifiers: NCT03486990 and NCT03738475.
Authors: Daniel R Getts; Danielle M Turley; Cassandra E Smith; Christopher T Harp; Derrick McCarthy; Emma M Feeney; Meghann Teague Getts; Aaron J Martin; Xunrong Luo; Rachael L Terry; Nicholas J C King; Stephen D Miller Journal: J Immunol Date: 2011-08-05 Impact factor: 5.422
Authors: Derrick P McCarthy; Zoe N Hunter; Bryce Chackerian; Lonnie D Shea; Stephen D Miller Journal: Wiley Interdiscip Rev Nanomed Nanobiotechnol Date: 2014-03-10
Authors: Prashant Singh; Ananya Arora; Tor A Strand; Daniel A Leffler; Carlo Catassi; Peter H Green; Ciaran P Kelly; Vineet Ahuja; Govind K Makharia Journal: Clin Gastroenterol Hepatol Date: 2018-03-16 Impact factor: 11.382
Authors: Tobias L Freitag; Joseph R Podojil; Ryan M Pearson; Frank J Fokta; Cecilia Sahl; Marcel Messing; Leif C Andersson; Katarzyna Leskinen; Päivi Saavalainen; Lisa I Hoover; Kelly Huang; Deborah Phippard; Sanaz Maleki; Nicholas J C King; Lonnie D Shea; Stephen D Miller; Seppo K Meri; Daniel R Getts Journal: Gastroenterology Date: 2020-02-04 Impact factor: 22.682
Authors: Kenneth E Truitt; A James M Daveson; Hooi C Ee; Gautam Goel; James MacDougall; Kristin Neff; Robert P Anderson Journal: Aliment Pharmacol Ther Date: 2019-08-13 Impact factor: 8.171
Authors: A I Lahdenperä; V Hölttä; T Ruohtula; H M Salo; L Orivuori; M Westerholm-Ormio; E Savilahti; K Fälth-Magnusson; L Högberg; J Ludvigsson; O Vaarala Journal: Clin Exp Immunol Date: 2012-02 Impact factor: 4.330
Authors: Govind K Makharia; Prashant Singh; Carlo Catassi; David S Sanders; Daniel Leffler; Raja Affendi Raja Ali; Julio C Bai Journal: Nat Rev Gastroenterol Hepatol Date: 2022-01-03 Impact factor: 46.802
Authors: Joseph R Podojil; Samantha Genardi; Ming-Yi Chiang; Sandeep Kakade; Tobias Neef; Tushar Murthy; Michael T Boyne; Adam Elhofy; Stephen D Miller Journal: J Immunol Date: 2022-06-20 Impact factor: 5.426
Authors: Eileah Loda; Gabriel Arellano; Gina Perez-Giraldo; Stephen D Miller; Roumen Balabanov Journal: Front Neurol Date: 2021-12-20 Impact factor: 4.003
Authors: Kuang-Yuh Chyu; Xiaoning Zhao; Jianchang Zhou; Paul C Dimayuga; Nicole Wm Lio; Bojan Cercek; Noah T Trac; Eun Ji Chung; Prediman K Shah Journal: JCI Insight Date: 2022-06-08